HERIZON: A Phase II Study of HER-Vaxx (IMU-131), a HER2targeting Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with HER2+advanced Stomach Cancer - Dose-dependent Anti-Cancer Antibodies Correlating with Improved Clinical Outcome
ANNALS OF ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要